AL淀粉样变性十年生存者的特征与治疗模式
该研究纳入186例自诊断起生存≥10年的AL淀粉样变性患者,占总体人群22%。这些患者具有良好的患者、器官和浆细胞特征,trisomies较少见;
要点
- 十年生存者占AL淀粉样变性总人群22%,具有较好的患者、器官和浆细胞特征。
- 十年生存者中trisomies较未达十年生存者少见。
- 完全血液学缓解和无心脏受累是无治疗生存期的独立预测因素。
核心结论
- AL淀粉样变性长期生存者日益增多,具有独特的患者、器官和克隆性疾病特征。
研究设计与样本
- 研究纳入自诊断起生存≥10年的AL淀粉样变性患者186例,占总体人群22%。
主要发现
- 十年生存者具有较好的患者、器官和浆细胞特征,trisomies较未达十年生存者少见。
- 全时最佳血液学缓解:完全缓解67%,非常好的部分缓解30%,部分缓解2%,无缓解1%。
- 一线治疗总体器官缓解率76%,考虑后续治疗线后增至86%。
- 多变量分析中,达到完全血液学缓解和无心脏受累是无治疗生存期的独立预测因素。
关键数值与推荐
- 全时最佳血液学缓解:完全缓解67%,非常好的部分缓解30%,部分缓解2%,无缓解1%。
- 11%的患者因一线治疗反应不足接受了巩固策略。
- 一线治疗总体器官缓解率76%,考虑后续治疗线后为86%。
临床怎么用
- 达到完全血液学缓解和无心脏受累与十年生存者更长的无治疗生存期相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improvement in survival in Light chain (AL) amyloidosis has been seen over recent decades, enabling more patients to achieve long-term survival. Patients with AL amyloidosis who survived ≥10 years from time of diagnosis (n = 186) were the subject of this study. Ten-year survivors represented 22% of the total population. These patients were characterized by favourable patient, organ and plasma cell features. Of note, trisomies were less common among 10-year survivors compared to those who did not survive to 10 years. All-time best haematological response was complete response in 67%, very good partial response in 30%, partial response in 2% and no response in 1%, with 11% having received a consolidative strategy for inadequate response to first line therapy. The overall organ response rate to first-line therapy was 76%, which increased to 86% when considering subsequent line(s) of therapy. Forty-seven percent of the 10-year survivors did not require a second-line therapy. The median treatment-free survival (TFS) among the 10-year survivors was 10·5 years (interquartile range 7·4-12·2). On multivariate analysis independent predictors for TFS were the achievement of complete haematological response and lack of cardiac involvement. Long-term survivors are increasingly seen in AL amyloidosis and present distinct patient, organ and clonal disease features.
引用
- Muchtar E, Gertz MA, Lacy MQ, et al. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol. 2019. PMID: 31298751. doi:10.1111/bjh.16096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。